SA PRO
Free Account
Solid Biosciences Inc.SLDBNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 76% recommend buying.

Consensus Rating
Buy
21 analysts·High coverage
76%
Rating Distribution
Strong Buy
00%
Buy
1676%
Hold
524%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 92% higher.

Bear Case
$9.00
+38%
Consensus
$12.50
+92%
Bull Case
$16.00
+146%
Price Range21 analysts
Low
Consensus
High
$9.00
$16.00
Current Target
Current Price
$6.50
Upside to Target
$6.00

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Dec 4, 2025Needham
Solid Biosciences initiated with a Buy at Needham
Target:$16.00
+208.3%from $5.19
Nov 4, 2025Barclays
Solid Biosciences price target lowered to $9 from $10 at Barclays
Target:$9.00
+73.1%from $5.20
Jul 21, 2025Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight Rating on Solid Biosciences (SLDB)
Target:$16.00
+136.7%from $6.76
Jun 24, 2024Leerink Partners
Leerink Partners Upgrades Solid Biosciences (SLDB) to Outperform
Target:$12.00
+81.3%from $6.62
May 31, 2024Piper Sandler
Solid Biosciences transferred with Overweight rating at Piper Sandler
Target:$20.00
+161.8%from $7.64
May 16, 2024Barclays
Solid Biosciences price target lowered to $18 from $21 at Barclays
Target:$18.00
+85.8%from $9.69
Mar 13, 2024Raymond James
Piper Sandler Upgrades Solid Biosciences (SLDB) to Overweight, 'Still See Significant Upside Potential Despite Recent Move'
Target:$20.00
+63.5%from $12.23

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance